Schizophrenia hospitalization in the US 2005–2014

Examination of trends in demographics, length of stay, and cost

Ethan Chen, MD, a Shahrzad Bazargan-Hejazi, PhD b,c, Chizobam Ani, MD, PhD d, David Hindman, PhD d,e, Deyu Pan, MS f, Gul Ebrahim, MD, BS f, Anaheed Shirazi, MD g, Jim E. Banta, PhD, MPH h

Abstract

Primarily we aimed to examine the crude and standardized schizophrenia hospitalization trend from 2005 to 2014. We hypothesized that there will be a statistically significant linear trend in hospitalization rates for schizophrenia from 2005 to 2014. Secondarily we also examined trends in hospitalization by race/ethnicity, age, gender, as well as trends in hospitalization Length of Stay (LOS) and inflation adjusted cost.

In this observational study, we used Nationwide Inpatient Sample data and International Classification of Diseases, Eleventh Revisions codes for Schizophrenia, which revealed 6,122,284 cases for this study. Outcomes included crude and standardized hospitalization rates, race/ethnicity, age, cost, and LOS. The analysis included descriptive statistics, indirect standardization, Rao-Scott Chi-Square test, t-test, and adjusted linear regression trend.

Hospitalizations were most prevalent for individuals ages 45–64 (38.8%), African Americans were overrepresented (25.8% of hospitalizations), and the gender distribution was nearly equivalent. Mean LOS was 9.08 days (95% confidence interval 8.71–9.45). Medicare was the primary payer for most hospitalizations (55.4%), with most of the costs ranging from $10,000-$49,999 (57.1%). The crude hospitalization rates ranged from 790–1142/100,000 admissions, while the US 2010 census standardized rates were 380–552/100,000 from 2005–2014. Linear regression trend analysis showed no significant difference in trend for race/ethnicity, age, nor gender (P > .001). The hospitalizations’ overall rates increased while LOS significantly decreased, while hospitalization costs and Charlson’s co-morbidity index increased (P < .001).

From 2005–2014, the overall US hospitalization rates significantly increased. Over this period, observed disparities in hospitalizations for middle-aged and African Americans were unchanged, and LOS has gone down while costs have gone up. Further studies addressing the important disparities in race/ethnicity and age and reducing costs of acute hospitalization are needed.

Abbreviations: CCI = Charlson’s co-morbidity index, DSM-IV = diagnostic and statistical manual of mental disorders, 4th edition, HCUP = Healthcare Cost and Utilization Project, ICD-9 = International Classification of Diseases, Eleventh Revisions, LOS = length of hospital stay, NIS = Nationwide Inpatient Sample, SE = standard error.

Keywords: age disparity, hospitalization cost, racial disparity, schizophrenia disparity, schizophrenia hospitalizations, schizophrenia trends
1. Introduction

Schizophrenia is a chronic, relapsing, mental disorder with an estimated prevalence of ∼1% in the US,[1,2] and is among the top 15 leading causes of disability in the world.[3] In 2013, the economic burden of schizophrenia was estimated to be $155.7 billion in the US.[4] Patients with schizophrenia have reduced life expectancy, increased disability,[5,6] an increased risk of dying prematurely due to chronic co-morbid medical conditions,[7,8] and a high suicide rate of 4.9% compared to the general population.[9]

Evidence of racial disparities in receiving diagnosis of schizophrenia is evident in research.[10] According to a report from a US national data non-Hispanic whites, and Hispanics were 3.15 times more likely to receive schizophrenic diagnosis.[11] In a different study African American, in compared to their white counter parts were over three times more likely to be diagnosed with schizophrenia.[12,13] a finding that is supported in other studies.[13-16]

Age of onset and gender are accepted as having powerful influence on its clinical progression and prognosis.[17-19] The average age of onset for schizophrenia is 18 in males and 25 and 35 in females.[20] Early age of onset,[21,22] and co-morbid condition, among other factors, partake in hospitalization for schizophrenia.[23] They also are risk factors for having poorer prognosis with longer hospital stays, more frequent hospital admissions, and a higher likelihood of readmission upon discharge, and subsequently substantial economic burden for the patient.[2,24,25] While there are no gender differences in the prevalence of schizophrenia, but there is gender difference in age of onset.[26] Males are 1.4 times more likely to be diagnosed compared to females.[27,28]

In general, the trends in rates of acute hospitalization can give us a metric of how effectively the condition is being treated. From 1996 to 2007 in the US, Blader investigated the trend in psychiatric hospitalizations, including schizophrenia, and found increasing psychiatric hospitalizations for children, adolescents, and adults while there was a decline in such rate for the elderly. The investigators, however, did not utilize a nationally representative sample.[29]

Of the studies conducted outside of the US to investigate schizophrenia-related hospitalization trends, few have utilized a nationally representative sample.[30-33] Subsequently, this study’s primary aim is to examine the crude and standardized schizophrenia hospitalization rates in the US from 2005–2014. We hypothesized that there would be a statistically significant linear trend in hospitalization rates for schizophrenia from 2005–2014. Additionally, we also examined trends in hospitalization by race/ethnicity, age, gender, and trends in hospitalization Length of Stay (LOS) and inflation-adjusted cost. Secondly, we hypothesized a significant difference among age groups, race/ethnicity, gender, LOS, and hospital cost. Our findings could improve our current understanding of patterns of schizophrenia among populations within the US. This knowledge is needed to identify risk factors further and delineate strategies for adequate provision of patient care, reduce hospitalization, LOS, therefore, reduce the health care cost, or least rethink resources distribution.

2. Methods

2.1. Study design and data

We conducted a cross-sectional study design using the Nationwide Inpatient Sample (NIS) database, which is a large hospital-based administrative national dataset, including hospital discharges from 2005 to 2014. The NIS was developed as part of the Healthcare Cost and Utilization Project (HCUP), a federal-state-industry partnership sponsored by the Agency for Healthcare Research and Quality. The NIS was designed to approximate a stratified 20% sample of all nonfederal, short-term, general, and specialty hospitals serving adults in the United States. The sampling strategy selected hospitals within states that have state

---

Table 1

ICD-9-DSM-IV inclusion and exclusion codes.

| Inclusion ICD-9 codes | Exclusion ICD-9 codes |
|-----------------------|-----------------------|
| 295.0 - Simple type schizophrenia | 292.9 - Pathological drug intoxication |
| 295.1 - Disorganized type schizophrenia | 292.1 - Drug-induced psychotic disorders |
| 295.2 - Catatonic type schizophrenia | 292.11 - Drug-induced psychotic disorder with delusions |
| 295.3 - Paranoid type schizophrenia | 292.12 - Drug-induced psychotic disorder with hallucinations |
| 295.4 - Schizophreniform disorder | 292.89 - Other drug-induced mental disorder |
| 295.5 - Latent schizophrenia | 305.3 - Hallucinogen abuse |
| 295.6 - Residual type schizophrenia | 305.6 - Cocaine abuse |
| 295.7 - Schizoaffective disorder | 305.7 - Amphetamine or related acting sympathomimetic abuse |
| 295.8 - Other specified types of schizophrenia | 305.8 - Other alcohol-induced mental disorders |
| 295.9 - Unspecified schizophrenia | 305.9 - Alcohol withdrawal, withdrawal syndrome or symptoms |

ICD-9-DSM-IV = International Classification of Diseases, Ninth Revision, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
2.2. Patient selection

To analyze schizophrenia hospitalizations, we identified and included all discharges for which the age of the patient hospitalized was 18 or older with International Classification of Diseases, Eleventh Revisions -Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) codes of schizophrenia as indicated in the 1st column in Table 1. We controlled for confounding variables by excluding hospitalizations with one day or less and psychosis induced by substance or alcohol use by excluding International Classification of Diseases, Eleventh Revisions DSM-IV codes listed in the exclusion column in Table 1.

Other variables used in the analysis were as follows:

1. demographic variables including age, gender, race, and ethnicity;
2. total in-hospital charges
3. insurance status described as Medicare, Medicaid, private insurance, and other;
4. length of hospital stay;
5. in-hospital mortality and
6. Charlson’s comorbidity index (CCI), derived from the HCUP medical comorbidity classification system.

The CCI was developed in 1987 and is used to measure the burden of co-morbidity by assessing 19 different disease comorbidity categories, each allocated a weight of 1 to 6 based on the adjusted relative risk of 1-year mortality and summed to provide a total score that is an indicator of disease burden and a reliable estimator of mortality.

2.3. Statistical analysis

We computed descriptive statistics for all variables. To investigate age-related trends in hospitalizations for schizophrenia, we constructed three age groups of 18 to 44, 45 to 64, and 65 + and standardized these age groups to the 2010 the US census age groups.

We performed bivariate analysis through the Rao-Scott Chi-square test and T-test to detect any significant differences in the primary variables over time. Subsequently, we conducted an linear regression trend analysis to explore any changes from 2005 to 2014 in hospitalizations for schizophrenia.

Appropriate analytical adjustments were made using sample stratum, cluster, and discharge weight variables consistent with design and analysis requirements for the NIS data sample poststratification to the US population. Standard errors (SE) for the computed statistics were reported using methods the NIS dataset analysis methods. All data analyses were conducted using SAS 9.1 (SAS Institute, Cary, NC). Statistical hypotheses were tested using \( \alpha \) less than 0.01 as the threshold for statistical significance. Data are presented with weighted \( n \pm SE \), weighted \% ± SE, or mean with 95% confidence interval.

### Table 2

| Variables                  | Weighted n | Weighted % (SE) |
|----------------------------|------------|-----------------|
| **Age (yr)**               |            |                 |
| 18–44                      | 1647036    | 32.51 (0.54)    |
| 45–64                      | 1966026    | 38.81 (0.23)    |
| >65 yr                     | 1453278    | 28.69 (0.60)    |
| **Race**                   |            |                 |
| White                      | 3000973    | 59.23 (1.12)    |
| African American           | 1311140    | 25.88 (0.77)    |
| Hispanic                   | 470020     | 9.26 (0.83)     |
| Other\(^1\)                | 284208     | 5.61 (0.34)     |
| **Gender**                 |            |                 |
| Male                       | 2580702    | 50.94 (0.32)    |
| Female                     | 2485683    | 49.06 (0.32)    |
| **Co-morbid medical conditions** |         |                 |
| Cardiovascular disease     | 250198     | 4.91 (0.13)     |
| Chronic pulmonary disease  | 1234119    | 24.36 (0.32)    |
| Congestive heart failure   | 478081     | 9.44 (0.21)     |
| Connective tissue disease  | 59259      | 1.17 (0.03)     |
| Dementia                   | 240368     | 4.74 (0.1687)   |
| Diabetes with complications| 110006     | 2.17 (0.05)     |
| Diabetes without complications| 1099976   | 21.71 (0.21)    |
| Metastatic carcinoma       | 81172      | 1.60 (0.05)     |
| Mild liver disease         | 159860     | 3.16 (0.07)     |
| Moderate to severe liver disease | 33872  | 0.67 (0.03)     |
| **Primary payer**          |            |                 |
| Medicare                   | 2808950    | 55.44 (0.59)    |
| Medicaid                   | 1354011    | 26.73 (0.60)    |
| Private                    | 498989     | 9.85 (0.29)     |
| Other\(^1\)                | 404390     | 7.98 (0.35)     |
| **Total in-hospital charge**|          |                 |
| <$10,000                   | 1481012    | 29.23 (0.69)    |
| $10,000–$49,999            | 2895462    | 57.15 (0.46)    |
| >$50,000                   | 689866     | 13.62 (0.45)    |
| **Mortality**              |            |                 |
| Alive                      | 4991029    | 98.65 (0.04)    |
| Dead                       | 68440      | 1.35 (0.04)     |

CCI=Charlson’s co-morbidity index, CI=confidence interval, LOS=length of stay, SE=standard error.

\(^1\) Includes participants with \( \geq 1 \) hospital stay day.

\(^2\) Other race includes Asian or PI, Native American, Other.
3. Results

After incorporating the study inclusion and exclusion criteria, the total number of hospitalizations for schizophrenia were 1,483,791 and, post-extrapolation to obtain a nationwide estimate yielded a weighted sample of 6,122,284 (Table 2). Slightly over thirty-eight percent (38.8%) of the hospitalization cases were in the 45–64 age group, 25.9% were African American, 55.4% covered by Medicare, 24.4% had co-morbidity with chronic pulmonary disease, and 21.7% with uncomplicated diabetes, and mean CCI was 1.2 (1.17–1.24). The mean LOS was 9.08 days (8.71–9.45), and 57.2% of total in-hospital charges cost $10,000-$49,999. Mortality for individuals while being hospitalized for schizophrenia was 1.4% from 2005–2014.

As indicated in Table 3 and Figure 1, the number of hospitalizations has been increasing from 2005 to 2014 for 453,020 to 722,415 hospitalizations, respectively. Despite the increasing hospitalizations, the percentage of hospitalizations by race/ethnicity were not significantly different throughout this decade (Fig. 2). When examining hospitalizations by age, we observed that the hospitalization rate for all age groups has increased before and after age standardization to the 2010 US Census age groups (Figs. 3 and 4). However, post standardization, there was an evident difference in the rate of hospitalizations between the 18 to 44 and 45 to 64 age groups (Fig. 4), whereas, before standardization, the rates were similar (Fig. 3).

From 2005 to 2014, the percentage of hospitalizations for males was up trending from 49.9% to 52.9% while, for females, it was down-trending from 50.1% to 47.4% (Table 3 and Fig. 5). Over this decade, the LOS for persons hospitalized with schizophrenia decreased by nearly a day (Fig. 6), and the percentage of charges were higher, with 61.5% of hospitalizations costing $10,000-$49,999 (Fig. 7). The percentage of hospitalizations costing ≥$50,000 have more than doubled from 10.4% to 21.3% while hospitalizations costing < $10,000 declined from 35.2% to 17.3%. Charlson’s co-morbidity index has been slightly up-trending from 1.07 to 1.40 in this period (Table 3 and Fig. 8).

After performing linear regression, there was no significant difference among age groups, race/ethnicity, nor gender since P > 0.001 (Table 4). However, we found a significant difference when comparing age-adjusted hospitalization rates (P < .001). In addition, the difference for LOS, hospital cost and CCI was significant with P = .006, P < .001 and P < .001, respectively.

4. Discussion

We found a statistically significant linear trend in hospitalization rates for schizophrenia from 2005–2014. This may in part, be due to increased access for patients with mental health disorders after approval of the Affordable Care Act since March 23, 2010.[36] It may also be due to worsening of disease due to inadequate treatment, which is discussed by Chaudhari et al. as predominantly due to non-adherence with reasons that include medication side effects, polypharmacy, perception of treatment ineffectiveness, lack of finances, poor access to a nearby mental health facility, poor insight or poor social support.[137] Recent changes in diagnostic criteria with the implementation of the DSM-V in 2013 can be disqualified in influencing our findings of increased hospitalizations since 99.5% of patients with schizophrenia diagnosed by the DSM-IV would also meet schizophrenia criteria in DSM-V.[148]
Figure 1. Hospitalizations for persons with schizophrenia from 2005–2014.

Figure 2. Percent hospitalizations for persons with schizophrenia by race (Crude) from 2005–2014.

Figure 3. Crude hospitalization rate for persons with schizophrenia by age from 2005–2014.
Figure 4. Age adjusted [post standardization] hospitalization rate for persons with Schizophrenia by Age from 2005–2014.

Figure 5. Schizophrenia hospitalization by gender (Crude) from 2005–2014.

Figure 6. Mean length of stay of hospitalizations for patients with schizophrenia from 2005–2014.
When looking at hospitalizations trend with respect to race/ethnicity, there was no real significant difference. However, African Americans continue to overrepresent with schizophrenia as evident in previous studies, encompassing 25% of hospitalizations due to schizophrenia, but only representing 13.4% of the US population. This continuous disparity in the burden of schizophrenia amongst African Americans should be addressed in future studies.

When examining hospitalizations trend with respect to age, we found that there was no significant change. However, when standardizing each age group to the 2010 US Census age groups, there was an increase in hospitalizations amongst all age groups, with the highest hospitalization rate for individuals 18 to 44 and lowest for individuals older than 65. Studies of Fitch et al and Huang et al, may explain this finding, which reported younger individuals constituting more inpatient visits compared to older individuals due to poor medication adherence. Early medication nonadherence was found to be a predictor of poor drug adherence that leads to the pattern of disease relapse and hospitalization that is sustained throughout an individual’s life, which may explain the up-trending hospitalization rate for all standardized age groups. Furthermore, the decrease in hospitalization rate from younger to older age groups in every observed year could be due to low adherence in younger individuals. Young people underestimate the necessity of treatment, but as they age, they become more adherent as they acquire more insight about the illness course and necessity of treatment to remain symptom-free, resulting in fewer hospitalizations.

Although there was no significant difference amongst gender in hospitalizations, we still saw an up-trend in hospitalization for...
males while there was a down-trend for females over this decade. This may be due to differences in the presentation of schizophrenia symptoms between males and females. Males are known to have more negative symptoms and more severe clinical features,[26,28] therefore, higher indication of hospitalization. While females, approximately 50% fewer hospitalizations compared to men.[41] Females have also shown to be more compliant with their medications, which leads to better treatment outcomes.[42] Also, physiologic differences as a result of gender may be involved, where men require higher dosages of antipsychotics in contrast to women due to increased hepatic clearance.[43]

When looking at the mean LOS over this decade, there was a significant increase in the number of hospitalizations from 2005 to 2014. We also found that African Americans continue to be overrepresented with schizophrenia. Additionally, hospitalizations amongst all age groups increased with the highest hospitalization rate for the younger population and lowest for the older. We found no gender difference in hospitalization but an uptrend for males and a downturn for females across the study period. Furthermore, the overall costs for schizophrenia-related hospitalizations increased while the LOS decreased in hospitalization cases. Based on these findings, further studies are needed to shed some light on strategies to achieve equity in the management of schizophrenia in different populations to reduce hospitalizations and its continuous substantial economic burden. Additionally, future studies should closely investigate key determinants of LOS to ensure payment system reflects the needs of different populations burdened by schizophrenia.

Table 4

| Variable               | P value | Variable               | P value |
|------------------------|---------|------------------------|---------|
| 18–44 yr               | .021    | CCI                    | <.001   |
| 44–64 yr               | .020    | Male                   | .001    |
| > 65 yr                | .177    | Female                 | .001    |
| White                  | .104    | Hospitalization cost (Mean) | <.001 |
| African American       | .037    | LOS                    | .001    |
| Hispanic               | .701    | Age adjusted hospitalization rate/100,000 | <.001 |
| Other                  | .926    |                        |         |

CCI = Charlson’s co-morbidity index, LOS = Length of stay.
*Other race includes Asian or PI, Native American, Other.

4.1. Limitations

Our study has several limitations due to the nature of cross-sectional study design and relying on prior coding of diagnosis through an existing administrative database. However, the NIS has been repeatedly studied as a national dataset from “real-world” situations. We cannot relate our findings to any process of care, given the limited scope of clinical data available in the NIS database, as the unit of analysis is the hospitalization and not the patient. We also are unable to determine if the primary reason for hospitalization is due to schizophrenia based on the diagnosis order list in NIS, nor are we able to distinguish initial hospitalizations from repeat hospitalizations. Moreover, we followed the Census age groups, but that may not reflect the true nature of hospitalization trends for schizophrenia. Nevertheless, we proceeded with our grouping to allow for comparability with other studies. Similarly, our groupings by dollar amount for the total in-hospital charges may also not reflect the true nature of the cost trends reflecting hospitalizations for schizophrenia.

5. Conclusions

We found a significant increase in the number of hospitalizations from 2005 to 2014. We also found that African Americans continue to be overrepresented with schizophrenia. Additionally, hospitalizations amongst all age groups increased with the highest hospitalization rate for the younger population and lowest for the older. We found no gender difference in hospitalization but an uptrend for males and a downturn for females across the study period. Furthermore, the overall costs for schizophrenia-related hospitalizations increased while the LOS decreased in hospitalization cases. Based on these findings, further studies are needed to shed some light on strategies to achieve equity in the management of schizophrenia in different populations to reduce hospitalizations and its continuous substantial economic burden. Additionally, future studies should closely investigate key determinants of LOS to ensure payment system reflects the needs of different populations burdened by schizophrenia.

**Author contributions**

Conceptualization: Shahrzad Bazargan-Hejazi, Chizobam Ani, David Hindman, Deyu Pan, Gul Ebrahim, Jim. E. Banta.
Data curation: Chizobam Ani.
Formal analysis: Chizobam Ani, Deyu Pan.
Methodology: Shahrzad Bazargan-Hejazi, Deyu Pan, Jim. E. Banta.
Project administration: Shahrzad Bazargan-Hejazi.
Resources: Jim. E. Banta.
Supervision: Shahrzad Bazargan-Hejazi, Chizobam Ani, David Hindman, Jim. E. Banta.
Writing – original draft: Ethan Chen, Shahrzad Bazargan-Hejazi, Chizobam Ani.
Writing – review & editing: Shahrzad Bazargan-Hejazi, Chizobam Ani, Anaheed Shirazi, Gul Ebrahim.

**References**

[1] McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67–76.
[2] Huang A, Amos TB, Joshi K, et al. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. Journal of medical economics 2018;21:1026–35.
[3] 2017. Available at https://www.census.gov/quickfacts/fact/table/US/PST045218.

[4] Cloutier M, Aigbogun MS, Guerin A, et al. The Economic Burden of Schizophrenia in the United States in 2013. J Clin Psychiatry 2016; 77:764–71.

[5] Vigo D, Thornsjoft G, Atun R. Estimating the true global burden of mental illness. The Lancet Psychiatry 2016;5:171–8.

[6] Chong HY, Teoh SL, Wu DB-C, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat 2016; 12:337.

[7] Olsson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2013;72: 1172–81.

[8] Laursen TM, Nordenstof M, Mortensen PB. Excess early mortality in schizophrenia. Ann Rev Clin Psychol 2014;10:423–48.

[9] Dickerson F, Stallings C, Ogrenia A, et al. Mortality in schizophrenia: clinical and serological predictors. Schizophr Bull 2014;40:796–803.

[10] Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2003;60:247–53.

[11] Hamilton JE, Heads AM, Meyer TD, et al. Ethnic differences in the diagnosis of schizophrenia and mood disorders during admission to an academic safety-net psychiatric hospital. Psychiatr Res 2018;267:160–70.

[12] Blow FC, Zeber JE, McCarthy JF, et al. Ethnicity and diagnostic patterns in veterans with psychoses. Soc Psychiatry Psychiatr Epidemiol 2004;39:841–51.

[13] Eck SM, Bahorik AL, Newhill CE, et al. Interviewer-perceived honesty as a mediator of racial disparities in the diagnosis of schizophrenia. Psychiatr Serv 2012;63:873–80.

[14] Barnes A. Race, schizophrenia, and admission to state psychiatric hospitals. Adm Policy Ment Health 2004;31:241–52.

[15] Fearon P, Kirkbride JB, Morgan C, et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol Med 2006;36:1341–50.

[16] Durbin A, Rudoler D, Durbin J, et al. Examining patient race and area predictors of inpatient admission for schizophrenia among hospital users in California. J Immigr Minor Health 2014;16:1025–34.

[17] Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003;60:565–71.

[18] Leung MD DA, Cheu MRC Psych DP. Sex differences in schizophrenia, a review of the literature. Acta Psychiatrascandinavica 2000;101:3–38.

[19] Kao Y-C, Liu Y-P. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry 2010;10:63.

[20] Sham P, MacLean C, Kendler K. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand 1994;89:135–41.

[21] Fitch K, Lev-Ran S. The association between comorbid psychiatric diagnoses and hospitalization-related factors among individuals with schizophrenia. Compr Psychiatr 2019;89:7–15.

[22] Rabinowitz J, Levine SZ, Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 2006;88:96–101.

[23] Bao Y, Fisher J, Studnicki J. Racial differences in behavioral inpatient diagnosis: examining the mechanisms using the 2004 Florida Inpatient Discharge Data. J Behav Health Serv Res 2008;35:347–57.

[24] Li R, Ma X, Wang G, et al. Why sex differences in schizophrenia? J Transl Neurosci 2016;1:37–42.

[25] Rabinowitz J, Levine SZ, Hafner H. A population based elaboration of schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006. Pharmacoeconomics and drug safety 2012;21:989–96.

[26] Cloutier M, Aigbogun MS, Guerin A, et al. The Economic Burden of Schizophrenia in the United States in 2013. J Clin Psychiatry 2016; 77:764–71.

[27] Shank PC, MacLean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr Scand 1994;89:135–41.

[28] Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010;22:417–28.

[29] Blader JA, Basile L, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010;22:417–28.

[30] Wu CS, Lin YJ, Feng J. Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006. Pharmacoeconomics and drug safety 2012;21:989–96.

[31] Chiang CL, Chen PC, Huang LY, et al. Trends in the prevalence of medication adherence in schizophrenia in Taiwan, 1998–2005: a 10-year population-based cohort study. Soc Psychiatry Psychiatr Epidemiol 2017;52:163–73.

[32] Preti A, Miozzo P. Increase in first admissions for schizophrenia and other major psychoses in Italy. Psychiatr Res 2000;94:139–52.

[33] Ritter PL, Dal Pai D, Belmonte-de-Ábreu P, et al. Trends in elderly psychiatric admissions to the Brazilian public health care system. Revista brasileira de psiquiatria (Sao Paulo, Brazil: 1999) 2016;38:314–7.

[34] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.

[35] Zavaschi AP, Fuchs SC. The need for reappraisal of AIDS score weight of Charlson comorbidity index. J Clin Epidemiol 2007;60:867–8.

[36] Mark TL. The effect of the affordable care act on uninsured rates among individuals with mental and substance use disorders. Psychiatr Serv 2019;70:343.

[37] Chaudhari B, Saldanha D, Kadian A, et al. Evaluation of treatment adherence in outpatients with schizophrenia. Ind Psychiatry J 2017; 26:213–22.

[38] Mattila T, Koeter M, Wohlforth T, et al. Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. Schizophr Bull 2015;41:637–43.

[39] Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286–97.

[40] Pool VE, Elder ST. A selected review of the literature and an empirical analysis of drug treatment compliance by schizophrenic patients. Applied Psychology 1986;35:547–73.

[41] Desai PR, Lawson KA, Barner JC, et al. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J Manag Care Pharm 2013;19:468–77.

[42] Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32.

[43] Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry 2010;22:472–84.

[44] Ries RK, Russo J, Wengerson D, et al. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatr Serv 2000;51:210–2.

[45] McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenia patients. J Nerv Ment Dis 1984;172:412–6.

[46] Zavaschi AP, Fuchs SC. The need for reappraisal of AIDS score weight of Charlson comorbidity index. J Clin Epidemiol 2007;60:867–8.

[47] Mark TL. The effect of the affordable care act on uninsured rates among individuals with mental and substance use disorders. Psychiatr Serv 2019;70:343.

[48] Chaudhari B, Saldanha D, Kadian A, et al. Evaluation of treatment adherence in outpatients with schizophrenia. Ind Psychiatry J 2017; 26:213–22.

[49] Mattila T, Koeter M, Wohlforth T, et al. Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. Schizophr Bull 2015;41:637–43.

[50] Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286–97.

[51] Pool VE, Elder ST. A selected review of the literature and an empirical analysis of drug treatment compliance by schizophrenic patients. Applied Psychology 1986;35:547–73.

[52] Desai PR, Lawson KA, Barner JC, et al. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J Manag Care Pharm 2013;19:468–77.

[53] Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32.

[54] Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry 2010;22:472–84.

[55] Ries RK, Russo J, Wengerson D, et al. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatr Serv 2000;51:210–2.

[56] McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenia patients. J Nerv Ment Dis 1984;172:412–6.